eXoZymes Inc. (EXOZ)

eXoZymes (EXOZ) stock has experienced notable movements in the past six months, increasing by 33.22% in the past month and 71.86% over the last three months, with a 1.78% increase over the past year. Key events impacting the stock price include the launch of NCTx in May 2025, increased CEO compensation in June 2025, CEO Michael Heltzen's purchase of 1,040 shares in July 2025, an updated investor presentation and participation in investment conferences in October 2025, and a third-quarter 2025 update with new appointments in November 2025.

Demand for some of eXoZymes, Inc.'s product categories can exhibit seasonality, influenced by broader industry trends and consumer behavior. Biofuels demand peaks during spring-summer, food flavors are highly seasonal, nutraceuticals see increased demand during cold and flu season, the beauty industry experiences seasonality, and molecular diagnostic test kits experience seasonal surges due to viral outbreaks. Protease enzymes see seasonal demand from food and pharmaceutical manufacturers.

eXoZymes, Inc. is a biotechnology company focused on developing and commercializing AI-engineered enzymes and cell-free biosolutions for various industrial applications, operating within the Health Care sector, specifically in the Biotechnology: Biological Products industry. The company specializes in enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing, aiming to replace traditional chemical production methods with sustainable alternatives. Its major products and solutions include enzyme modules and cell-free exozyme biosolutions, nucleic acid purification, amplification, and analysis workflows, molecular diagnostic test kits, biochemicals, and nutraceuticals.

eXoZymes, Inc. is headquartered in Monrovia, California, United States, and distributes its products through direct sales and a global network of distributors, serving academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide. The company has employees across North and South America.

eXoZymes has maintained a generally positive brand reputation in the past year, driven by its innovative technology and strategic developments. Articles in November 2025 positively showcased the company's spinout and its work in nutraceuticals and pharmaceuticals. In April 2025, news highlighted the launch of BioClick, supported by a $300K NIH grant. The rebranding from Invizyne Technologies, Inc. to eXoZymes, Inc. in February 2025 was a strategic move to bring clarity around its core technology.

eXoZymes (NASDAQ: EXOZ) has a mixed ownership structure, with approximately 0.74% to 0.90% held by institutional shareholders, 16.46% to 162.36% by insiders, and 0.00% to 82.80% by retail investors. Major institutional owners include Vanguard Group Inc., Geode Capital Management LLC, and BlackRock, Inc. Major individual insiders and entities with significant holdings include Mdb Capital Holdings LLC, Anthony Digiandomenico, and Christopher A. Marlett.